Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
Netherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands.
BMJ Open. 2022 Nov 17;12(11):e063134. doi: 10.1136/bmjopen-2022-063134.
Long-term survival after childhood cancer often comes at the expense of late, adverse health conditions. However, survivorship care is frequently not available for adult survivors in Europe. The PanCareFollowUp Consortium therefore developed the PanCareFollowUp Care Intervention, an innovative person-centred survivorship care model based on experiences in the Netherlands. This paper describes the protocol of the prospective cohort study (Care Study) to evaluate the feasibility and the health economic, clinical and patient-reported outcomes of implementing PanCareFollowUp Care as usual care in four European countries.
In this prospective, longitudinal cohort study with at least 6 months of follow-up, 800 childhood cancer survivors will receive the PanCareFollowUp Care Intervention across four study sites in Belgium, Czech Republic, Italy and Sweden, representing different healthcare systems. The PanCareFollowUp Care Intervention will be evaluated according to the Reach, Effectiveness, Adoption, Implementation and Maintenance framework. Clinical and research data are collected through questionnaires, a clinic visit for multiple medical assessments and a follow-up call. The primary outcome is empowerment, assessed with the Health Education Impact Questionnaire. A central data centre will perform quality checks, data cleaning and data validation, and provide support in data analysis. Multilevel models will be used for repeated outcome measures, with subgroup analysis, for example, by study site, attained age, sex or diagnosis.
This study will be conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. The study protocol has been reviewed and approved by all relevant ethics committees. The evidence and insights gained by this study will be summarised in a Replication Manual, also including the tools required to implement the PanCareFollowUp Care Intervention in other countries. This Replication Manual will become freely available through PanCare and will be disseminated through policy and press releases.
Netherlands Trial Register (NL8918; https://www.trialregister.nl/trial/8918).
儿童癌症患者的长期生存通常是以晚年不良健康状况为代价的。然而,欧洲的成年幸存者往往无法获得生存者护理。因此,泛癌生存者随访关怀联盟开发了泛癌生存者随访关怀干预措施,这是一种基于荷兰经验的创新的以患者为中心的生存者关怀模式。本文介绍了前瞻性队列研究(关怀研究)的方案,该研究旨在评估在比利时、捷克共和国、意大利和瑞典的四个研究地点将泛癌生存者随访关怀干预措施作为常规护理实施的可行性,以及其在健康经济学、临床和患者报告结果方面的效果。
在这项前瞻性、纵向队列研究中,至少有 6 个月的随访期,800 名儿童癌症幸存者将在比利时、捷克共和国、意大利和瑞典的四个研究地点接受泛癌生存者随访关怀干预措施,这四个研究地点代表了不同的医疗保健系统。将根据 Reach、Effectiveness、Adoption、Implementation 和 Maintenance 框架评估泛癌生存者随访关怀干预措施。通过问卷调查、多次医疗评估的诊所就诊和随访电话收集临床和研究数据。主要结局是通过健康教育培训影响问卷评估的赋权。一个中央数据中心将进行质量检查、数据清理和数据验证,并在数据分析方面提供支持。将使用多级模型对重复的结果测量进行分析,例如,通过研究地点、获得年龄、性别或诊断进行亚组分析。
本研究将按照良好临床实践和赫尔辛基宣言的准则进行。研究方案已得到所有相关伦理委员会的审查和批准。通过这项研究获得的证据和见解将在一份复制手册中进行总结,该手册还包括在其他国家实施泛癌生存者随访关怀干预措施所需的工具。该复制手册将通过泛癌联盟免费提供,并通过政策和新闻稿传播。
荷兰试验注册处(NL8918;https://www.trialregister.nl/trial/8918)。